中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
2023 NO.12

Theme Issue: 

Diagnosis and treatment of pancreatic disease-related dyspepsia

Executive Chief Editor: FU Deliang
Huashan Hospital of Fudan University
Cover Content

 Previous Issue | Next Issue 

Display Method:
Editorial
The diagnosis and treatment of pancreatic disease-related dyspepsia
Xiaoyi WANG, Deliang FU
2023, 39(12): 2753-2756. DOI: 10.3969/j.issn.1001-5256.2023.12.001
Abstract(678) HTML (309) PDF (592KB)(177)
Abstract:
Various pancreatic diseases can cause dyspepsia due to pancreatic exocrine insufficiency （PEI） caused by pancreatic parenchymal injury and/or pancreatic duct obstruction， which further leads to impaired digestive function and a series of severe clinical outcomes such as malnutrition， weight loss， an...
Expert Forum
Advances in the diagnosis and treatment of dyspepsia in chronic pancreatitis patients
Lianghao HU, Zhendong JIN
2023, 39(12): 2757-2762. DOI: 10.3969/j.issn.1001-5256.2023.12.002
Abstract(717) HTML (335) PDF (575KB)(125)
Abstract:
Dyspepsia is a common group of clinical symptoms and can be classified into organic and functional dyspepsia. Patients with chronic pancreatitis （CP） often have the symptoms of dyspepsia such as fatty diarrhea， abdominal distention， and abdominal pain， and most patients have pancreatic exocrine insu...
Current status of the diagnosis and treatment of pancreatic exocrine insufficiency after pancreatectomy
Ning PU, Yanfei AN, Wenhui LOU
2023, 39(12): 2763-2769. DOI: 10.3969/j.issn.1001-5256.2023.12.003
Abstract(482) HTML (261) PDF (605KB)(94)
Abstract:
Dyspepsia due to pancreatic exocrine insufficiency is a common complication after pancreatectomy； however， due to the lack of simple， efficient， and unified diagnostic methods， standardized treatment standards， and awareness of this disease among surgeons， it is difficult to get adequate diagnosis a...
Diagnosis and treatment of dyspepsia associated with pancreatic tumors
Guodong SHI, Zipeng LU, Kuirong JIANG
2023, 39(12): 2770-2774. DOI: 10.3969/j.issn.1001-5256.2023.12.004
Abstract(522) HTML (147) PDF (569KB)(70)
Abstract:
Dyspepsia is the one of the most common clinical manifestations of digestive system diseases and has various and complex causes， among which pancreatic tumor is a relatively uncommon cause and is easily neglected in clinical practice. The dual factors of tumor and dyspepsia may cause a significant r...
Guideline
Chinese expert consensus on targeted immunotherapy combined with local therapy for advanced hepatocellular cancer
Liver Oncology Branch, China Association for the Promotion of International Exchange in Healthcare, Immunology Branch
2023, 39(12): 2782-2792. DOI: 10.3969/j.issn.1001-5256.2023.12.006
Abstract(792) HTML (1111) PDF (908KB)(465)
Abstract:
Key points in hepatitis C guidance 2023 update： American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing， managing， and treating hepatitis C virus infection
Huiying RAO
2023, 39(12): 2798-2803. DOI: 10.3969/j.issn.1001-5256.2023.12.008
Abstract(562) HTML (293) PDF (525KB)(189)
Abstract:
The Infectious Diseases Society of America and the American Association for the Study of Liver Diseases have collaboratively developed evidence-based guidance regarding the diagnosis， management， and treatment of hepatitis C virus （HCV） infection since 2013. A panel of clinicians and investigators w...
Key points in pancreatic cancer： ESMO clinical practice guideline for diagnosis， treatment and follow-up （2023）
Zheran CHEN, Lei XIN, Luowei WANG
2023, 39(12): 2804-2808. DOI: 10.3969/j.issn.1001-5256.2023.12.009
Abstract(820) HTML (237) PDF (1010KB)(211)
Abstract:
In September 2023， the European Society for Medical Oncology published Pancreatic cancer： ESMO Clinical Practice Guideline for diagnosis， treatment and follow-up in Annals of Oncology. The guideline provides recommendations on the epidemiology， diagnosis， and treatment of pancreatic cancer （PC）. The...
Viral Hepatitis
Predictors of HBsAg clearance in HBeAg-negative chronic hepatitis B patients treated with pegylated interferon α-2b and the construction of a nomogram model
Jialu WANG, Deyang XI, Xuebing YAN, Fang JI, Chunyang LI
2023, 39(12): 2809-2816. DOI: 10.3969/j.issn.1001-5256.2023.12.010
Abstract(567) HTML (261) PDF (1393KB)(97)
Abstract:
Objective To establish an early predictive model using serological markers based on LASSO regression for predicting the possibility of HBsAg clearance in HBeAg-negative chronic hepatitis B （CHB） patients treated with pegylated interferon α-2b （PEG-IFNα-2b）， and to investigate the diagnostic value of...
Autoimmune Liver Disease
Effect of depression on response to ursodeoxycholic acid and the occurrence of liver cirrhosis in patients with primary biliary cholangitis
Haifeng LIU, Simin ZHOU, Jiwen LI, Jiangpeng LIU, Bangmao WANG, Lu ZHOU
2023, 39(12): 2817-2823. DOI: 10.3969/j.issn.1001-5256.2023.12.011
Abstract(488) HTML (164) PDF (868KB)(72)
Abstract:
Objective Depression is common in patients with primary biliary cholangitis （PBC）， but the role of depression in disease progression remains unclear. This study aims to investigate the association between depression and treatment response and the impact of depression on liver cirrhosis in PBC patien...
Liver Fibrosis and Liver Cirrhosis
Association between spontaneous portosystemic shunt and hepatorenal syndrome in liver cirrhosis
Huan ZHANG, Tenglong XING, Pan ZHANG, Runrun SHANG, Mingmei WANG, Yuying ZHAO, Wanbo XU
2023, 39(12): 2824-2830. DOI: 10.3969/j.issn.1001-5256.2023.12.012
Abstract(475) HTML (142) PDF (776KB)(67)
Abstract:
Objective To investigate the association between spontaneous portosystemic shunt （SPSS） and hepatorenal syndrome （HRS） in patients with liver cirrhosis. Methods A retrospective analysis was performed for 93 patients with SPSS from Dezhou Hospital， Qilu Hospital of Shandong University， from January 2...
Clinical features of bone mass loss in liver cirrhosis and its association with sarcopenia
Qiu JIN, Jing YANG, Honglin MA, Zhenghao SUN, Qingqing LIU, Shaoshan HU, Pingju LI
2023, 39(12): 2831-2838. DOI: 10.3969/j.issn.1001-5256.2023.12.013
Abstract(435) HTML (137) PDF (750KB)(48)
Abstract:
Objective To investigate the influence of sarcopenia on bone mass loss， the risk factors for bone mass loss in liver cirrhosis， and the correlation between body composition and bone mineral density （BMD） by comparing the clinical features of bone mass loss in patients with liver cirrhosis. Methods A...
Value of Model for End-Stage Liver Disease score and albumin-bilirubin score combined with β2-microglobulin in predicting liver cirrhosis with acute kidney injury
Peng WANG, Zeyu LI, Yating JIANG, Cheng SHANG, Hong WANG
2023, 39(12): 2839-2844. DOI: 10.3969/j.issn.1001-5256.2023.12.014
Abstract(349) HTML (122) PDF (682KB)(39)
Abstract:
Objective To investigate the value of combined determination of Model for End-Stage Liver Disease （MELD） score， albumin-bilirubin （ALBI） score， and β2-microglobulin in the diagnosis of liver cirrhosis with acute kidney injury （AKI）. Methods Clinical data were collected from 258 patients with liver c...
Mechanism of microRNA-223-3p inhibiting hepatic stellate cell activation by targeting microtubule-associated protein 1B
Wentao XIE, Kangkang YU, Qi CHENG, Ning LI
2023, 39(12): 2845-2850. DOI: 10.3969/j.issn.1001-5256.2023.12.015
Abstract(336) HTML (221) PDF (1203KB)(43)
Abstract:
Objective To investigate the effect of microRNA-223-3p （miR-223-3p） on hepatic stellate cell （HSC） activation and its mechanism. Methods Human HSC LX2 cells were selected for the study， and LX2 cells were stimulated by TGF-β to establish a model of HSC activation； quantitative real-time PCR was used...
Efficacy of human umbilical cord mesenchymal stem cells via different transplantation approaches in treatment of rats with liver cirrhosis
Yingqi QIU, Hongwei WANG, Hongyan ZHU, Hongliang YU, Fan XIE, Cuibao JIANG
2023, 39(12): 2851-2857. DOI: 10.3969/j.issn.1001-5256.2023.12.016
Abstract(408) HTML (288) PDF (2070KB)(38)
Abstract:
Objective To investigate the therapeutic effect of the frozen and fresh preparations of human umbilical cord mesenchymal stem cells （hUC-MSC） on a rat model of liver cirrhosis after transplantation via the portal vein or the caudal vein. Methods A total of 70 specific pathogen-free healthy male Spra...
Liver Neoplasm
Role of HBV DNA polymerase in mediating the immune escape of tumor cells in HBV-related hepatocellular carcinoma
Hongxia LI, Yimeng SUN, Hongtao ZHANG, Shuwang HAN, Delin ZHANG, Haitao SHANG, Wu GUO, Junjian LIU, Zhonglian LI
2023, 39(12): 2858-2866. DOI: 10.3969/j.issn.1001-5256.2023.12.017
Abstract(411) HTML (121) PDF (2211KB)(44)
Abstract:
Objective To determine whether HBV DNA polymerase is associated with T-cell failure and thus mediates the immune escape of HBV-related hepatocellular carcinoma （HCC） tumor cells， and to investigate the specific molecular mechanisms. Methods Liver cancer cell lines Huh7 and HepG2 stably transfected w...
Other Liver Disease
Value of the serum levels of Clusterin and sphingosine 1-phosphate in assessing the prognosis of sepsis patients with acute liver injury
Dazhou XU, Shuxian ZHANG, Kun WANG, Chenyan ZUO, Yi ZENG, Qingwen YUAN, Zhimei ZHANG
2023, 39(12): 2867-2872. DOI: 10.3969/j.issn.1001-5256.2023.12.018
Abstract(410) HTML (110) PDF (699KB)(24)
Abstract:
Objective To investigate the value of the serum levels of Clusterin and sphingosine 1-phosphate （S1P） in assessing the prognosis of sepsis patients with acute liver injury. Methods A total of 127 sepsis patients with acute liver injury who were admitted to Lianyungang Hospital， Xuzhou Medical Univer...
Protective effect of Zhizi Dahuang decoction in a mouse model of alcoholic liver disease
Yiwen HOU, Rongjie ZHANG, Longshan JI, Qian LI, Yueqiu GAO, Man LI
2023, 39(12): 2873-2884. DOI: 10.3969/j.issn.1001-5256.2023.12.019
Abstract(527) HTML (111) PDF (3331KB)(44)
Abstract:
Objective To investigate the effect of Zhizi Dahuang decoction （ZZDHT） in the treatment of alcoholic liver disease （ALD） by improving oxidative stress in hepatic neutrophils. Methods Network pharmacology was used to obtain the chemical components of ZZDHT and their corresponding action targets and a...
Biliary Disease
Efficacy and safety of endoscopic retrograde cholangiopancreatography during pregnancy and puerperium： A comparative analysis
Ronglai CAO, Liang ZHU, Zhengping YU, Jinli HE, Youxiang CHEN
2023, 39(12): 2885-2893. DOI: 10.3969/j.issn.1001-5256.2023.12.020
Abstract(378) HTML (110) PDF (680KB)(29)
Abstract:
Objective To investigate the efficacy and safety of endoscopic retrograde cholangiopancreatography （ERCP） during pregnancy and puerperium through a comparative analysis. Methods A retrospective analysis was performed for the clinical data of 22 patients in pregnancy and 39 patients in puerperium who...
Pancreatic Disease
Establishment of a prognostic prediction model for pancreatic cancer based on endoplasmic reticulum stress-related genes
Shengnan LYU, Xinyu PENG, Jian ZHANG, Huan LIU, Feng WEI
2023, 39(12): 2894-2900. DOI: 10.3969/j.issn.1001-5256.2023.12.021
Abstract(431) HTML (311) PDF (1296KB)(37)
Abstract:
Objective To investigate the role of endoplasmic reticulum stress genes in the prognosis of pancreatic cancer， and to establish a prognostic prediction model based on the prognostic markers for pancreatic cancer. Methods Transcriptome sequencing data were downloaded from TCGA and GTEx databases， and...
New Technology and Therapeutic Strategy
Application of Mengchao Liver Disease-Brain System version 2.0 in artificial intelligence-assisted clinical diagnosis and treatment： A preliminary study
Haitao LI, Hongzhi LIU, Gouxu FANG, Pengfei GUO, Zhenwei CHEN, Jingfeng LIU
2023, 39(12): 2901-2907. DOI: 10.3969/j.issn.1001-5256.2023.12.022
Abstract(550) HTML (167) PDF (647KB)(41)
Abstract:
Objective To investigate the application of Mengchao Liver Disease-Brain System version 2.0 in clinical diagnosis and treatment. Methods This study was conducted among 160 patients who were admitted to the internal medicine and surgical departments from June 9 to 21， 2021， and their data were automa...
Review
Theory and practice of immunoregulatory therapy with traditional Chinese medicine for chronic hepatitis B
Xiaobin LI, Bowen LIU, Feng LI, Xiaopeng SU, Shiping HU
2023, 39(12): 2908-2913. DOI: 10.3969/j.issn.1001-5256.2023.12.023
Abstract(492) HTML (152) PDF (674KB)(56)
Abstract:
Chronic hepatitis B （CHB） is still a malignant infectious disease that seriously threatens human health， and currently nucleos（t）ide analogues and interferon are the main treatment methods for CHB， but they cannot achieve functional cure. The development and progression of CHB are closely associated...
Research advances in lean nonalcoholic fatty liver disease
Yujuan ZHANG, Xiqiao ZHOU
2023, 39(12): 2914-2919. DOI: 10.3969/j.issn.1001-5256.2023.12.024
Abstract(630) HTML (145) PDF (593KB)(119)
Abstract:
Nonalcoholic fatty liver disease （NAFLD） is currently the main cause of chronic liver disease worldwide， and it can progress to hepatitis， liver fibrosis， liver cirrhosis， and even hepatocellular carcinoma. Although obesity plays a key role in the development of NAFLD， more and more studies have con...
Research advances in mesenchymal stem cells and their exosomes in treatment of autoimmune hepatitis
Longlong LUO, Lifei WANG, Ying ZHENG, Bin LI, Lixia LU, Chuyi LI, Xiaohui YU, Jiucong ZHANG
2023, 39(12): 2920-2925. DOI: 10.3969/j.issn.1001-5256.2023.12.025
Abstract(563) HTML (150) PDF (830KB)(58)
Abstract:
Autoimmune hepatitis （AIH） is a type of chronic hepatitis caused by the autoimmune system attacking hepatocytes， and its chronic progression may lead to liver cirrhosis and even hepatocellular carcinoma. Currently， pharmacotherapy and liver transplantation are the main treatment methods for AIH， but...
Role of T lymphocytes in primary sclerosing cholangitis
Ziyi LI, Wanjie ZHANG, Fuchun WANG, Xiaorong MAO, Junfeng LI
2023, 39(12): 2926-2931. DOI: 10.3969/j.issn.1001-5256.2023.12.026
Abstract(398) HTML (215) PDF (803KB)(40)
Abstract:
Primary sclerosing cholangitis （PSC） is an immune-mediated chronic cholestatic liver disease and can progress to end-stage liver diseases such as liver cirrhosis and liver failure， and there are still no effective treatment methods at present. Studies have found that T lymphocytes are closely associ...
Research advances in signaling pathways associated with potential anti-liver fibrosis drugs and targets
Xin ZHOU, Zhi WANG, Xueru HE, Yuhao FU, Xuejiao XUN, Ying LI, Zhanjun DONG
2023, 39(12): 2932-2941. DOI: 10.3969/j.issn.1001-5256.2023.12.027
Abstract(541) HTML (448) PDF (1241KB)(99)
Abstract:
Liver fibrosis is a key step in the progression of chronic liver diseases to liver cirrhosis and even liver cancer. In recent years， a large number of studies have shown the necessity of intervening in the process of liver fibrosis， and various anti-liver fibrosis drugs and active ingredients have b...
Thoughts on the diagnosis and treatment of hepatic encephalopathy associated with blood ammonia in liver cirrhosis
Liang ZHANG, Hao LI, Shanhong TANG
2023, 39(12): 2942-2945. DOI: 10.3969/j.issn.1001-5256.2023.12.028
Abstract(473) HTML (426) PDF (529KB)(64)
Abstract:
Hepatic encephalopathy is a serious complication of liver cirrhosis and can cause neuropsychiatric symptoms such as cognitive impairment and motor impairment. More than 30% of patients with liver cirrhosis may develop hepatic encephalopathy， posing a huge economic burden to the health of patients an...
Mechanism of action of N7-methylguanosine in hepatocellular carcinoma
Chun GAO, Jingjing JIANG, Yuchun CHEN, Xiaohui YU, Jiucong ZHANG,
2023, 39(12): 2946-2951. DOI: 10.3969/j.issn.1001-5256.2023.12.029
Abstract(458) HTML (220) PDF (888KB)(30)
Abstract:
N7-methylguanosine （m7G） is one of the most popular RNA modifications at present and has attracted wide attention from researchers in China and globally. By influencing the metabolism of various RNA molecules （including messenger RNA， ribosomal RNA， microRNA， and transfer RNA）， m7G modification acti...
Regulatory role of mechanical forces in the formation of liver organoids
Ning WANG, Wenliang LYU
2023, 39(12): 2952-2958. DOI: 10.3969/j.issn.1001-5256.2023.12.030
Abstract(391) HTML (269) PDF (696KB)(52)
Abstract:
In recent years， the continuous advances in material sciences and techniques have helped with the establishment and development of liver organoids that can simulate the structure and function of organs in vivo. In addition to the research on traditional biological factors， the construction of microe...
Evaluation of cholestatic liver disease animal model based on clinical syndrome characteristics of integrated traditional Chinese and Western medicine
Zhengwang ZHU, Pingsheng ZHU, Mingsan MIAO
2023, 39(12): 2959-2964. DOI: 10.3969/j.issn.1001-5256.2023.12.031
Abstract(476) HTML (175) PDF (647KB)(24)
Abstract:
Cholestatic liver disease is a common disease of the hepatobiliary system. Its etiology and pathogenesis are complex. The establishment of an appropriate animal model of cholestatic liver disease is the basis for further study of its pathogenesis and prevention. This study summarized the existing mo...
Research advances in targeted therapy for gallbladder carcinoma
Liwen DU, Jiansheng LIU
2023, 39(12): 2965-2969. DOI: 10.3969/j.issn.1001-5256.2023.12.032
Abstract(799) HTML (398) PDF (562KB)(77)
Abstract:
Gallbladder carcinoma （GBC） is a type of malignant tumor with an extremely poor prognosis， and at present， surgical operation is the most effective treatment method for this disease. Unfortunately， due to a lack of typical symptoms in the early stage， most patients have progressed to the advanced st...
Changes in intestinal microbiota and application of probiotics in patients with acute pancreatitis
Yanqing LYU, Jiajie LI, Kunyu LIU, Ruhua GUO, Huifan JI
2023, 39(12): 2970-2977. DOI: 10.3969/j.issn.1001-5256.2023.12.033
Abstract(460) HTML (279) PDF (708KB)(56)
Abstract:
Intestinal microbiota is the most complex and important microecosystem in the human body， and gut microbiota dysbiosis is closely associated with the development and progression of acute pancreatitis. Targeted regulation of intestinal microecology in assisting the treatment of acute pancreatitis has...
Research advances in machine learning models for acute pancreatitis
Minyue YIN, Jinzhou ZHU, Lu LIU, Jingwen GAO, Jiaxi LIN, Chunfang XU
2023, 39(12): 2978-2984. DOI: 10.3969/j.issn.1001-5256.2023.12.034
Abstract(451) HTML (353) PDF (631KB)(77)
Abstract:
Acute pancreatitis （AP） is a gastrointestinal disease that requires early intervention， and when it progresses to moderate-severe AP （MSAP） or severe AP （SAP）， there will be a significant increase in the mortality rate of patients. Machine learning （ML） has achieved great success in the early predic...
Introduction of High - quality Articles in Foreign Journals
Hepatology International｜Association of nonmalignant portal vein thrombosis and clinical outcomes in patients with cirrhosis and acute variceal bleeding: a multicenter observational study
2023, 39(12): 2792-2792. DOI: 10.3969/j.issn.1001-5256.2023.12.gwjpwzjj1
Abstract(237) HTML (121) PDF (1325KB)(32)
Abstract:
Hepatology International｜A simpler definition of MAFLD precisely predicts incident metabolic diseases: a 7-year cohort study
2023, 39(12): 2941-2941. DOI: 10.3969/j.issn.1001-5256.2023.12.gwjpwzjj2
Abstract(250) HTML (242) PDF (846KB)(30)
Abstract:
Thanks
Current reviewers
2023, 39(12): 2595-2595. DOI: 10.3969/j.issn.1001-5256.2023.12.zhixie1
Abstract(208) HTML (128) PDF (842KB)(14)
Abstract:
    

The first journal specializing in hepatobiliary and pancreatic diseases in China

Supervisor：Ministry of Education of the People's Republic of China

Sponsor：Jilin University

Academic Support: Chinese Society of Hepatology，Chinese Medical Association

Address: 461 Xinjiang Road, Changchun

Submit：0431-88782044

Peer review：0431-88783542

Email：lcgdb@vip.163.com

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

YesterdayIP[2102]YesterdayPV[3388]TodayIP[77]TodayPV[82]Online[27]

Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd